Updated Friday, December 15, 2017
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 15, 2017   Issue 6,  Pages: 433–441

DOI: 10.1016/S2095-4964(17)60363-7
Review
Effects of herbal extracts and compounds and pharmacological agents on pulmonary fibrosis in animal models: a review
1. Hoda Mojiri-Forushani (Abadan School of Medical Sciences, Abadan 6313833177, Iran )
2. Ali Asghar Hemmati (Department of Pharmacology, the School of Pharmacy and Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran )
3. Mohammad Amin Dehghani (Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran )
4. Ali Reza Malayeri (Department of Pharmacology, the School of Pharmacy and Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran )
5. Hossein Hassan Pour (Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran )
ABSTRACT Pulmonary fibrosis, a chronic inflammatory disease that occurs mainly in older adults, is a serious health threat with few effective treatment options. The etiological aspects of pulmonary fibrosis remain unknown, though some factors such as cigarette smoking, viral infections, surfactant protein polymorphisms, and chronic or high doses use of certain drugs are considered to be risk factors for the progression of pulmonary fibrosis. No standard treatments have been introduced in clinic yet. Although glucocorticoids and antioxidant drugs have been administered, the severe and broad-spectrum adverse effects of glucocorticoids limit their use. Efforts to identify novel therapeutic agents with improved safety profiles are therefore ongoing. In this review, the authors have described the effects of herbal extracts and compounds and certain pharmacological agents on pulmonary fibrosis in animal models. These effects indicate that herbs are a promising source of compounds that can play pivotal roles in the treatment of lung fibrosis.
Welcome to JIM! You are the number 315 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Mojiri-Forushani H, Hemmati AA, Dehghani MA, Malayeri AR, Pour HH. Effects of herbsal extracts and compounds and pharmacological agents on pulmonary fibrosis in animal models: a review. J Integr Med. 2017; 15(6): 433–441.
References:
1Kikuchi N, Ishii Y, Morishima Y, Yageta Y, Haraguchi N, Itoh K, Yamamoto M, Hizawa N. Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance[J].Respir Res, 2010, 11(1): 31.  
2Naghani EE, Javadi I, Rashidinooshabadi M, Goudarzi M, Houshmand GR. Protective effects of hydroalcoholic extract of Hypericum perforatum against bleomycin-induced pulmonary fibrosis in rats[J].J Babol Univ Med Sci, 2016, 18(1): 44–51.  
3Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature[J].Eur Respir Rev, 2012, 21(126): 355–361.  
4Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11[J].Lancet Respir Med, 2014, 2(7): 566–572.  
5Lynch JP 3rd, Huynh RH, Fishbein MC, Saggar R, Belperio JA, Weigt SS. Idiopathic pulmonary fibrosis: epidemiology, clinical features, prognosis, and management[J].Semin Respir Crit Care Med, 2016, 37(3): 331–357.  
6Javadi I, Rashidi Nooshabadi M, Goudarzi M, Roudbari R. Protective effects of celery (Apium graveloens) seed extract on bleomycin-induced pulmonary fibrosis in rats[J].J Babol Univ Med Sci, 2015, 17(1): 70–76.  
7Bahrami-Karkevandi M, Moshtaghian SJ, Mahzoni P, Adibi S, Kazemi S. The effects of hydroalcoholic extract of Artemisia Aucheri on bleomycin induced pulmonary fibrosis in rats[J].J Shahrekord Univ Med Sci, 2011, 12(4): 33–40.  
8Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis[J].N Engl J Med, 2001, 345(7): 517–525.  
9Tang L, Jiang T, Han X, Chen D. Effect of tranilast on bleomycin-induced pulmonary fibrosis in a rat model[J].Afr J Pharm Pharmacol, 2011, 5(10): 1315–1320.  
10Ertekin A, Deger Y, Mert H, Mert N, Yur F, Dede S, Demir H. Investigation of the effects of alpha-tocopherol on the levels of Fe, Cu, Zn, Mn, and carbonic anhydrase in rats with bleomycin-induced pulmonary fibrosis[J].Biol Trace Elem Res, 2007, 116(3): 289.  
11Kakugawa T, Mukae H, Hishikawa Y, Ishii H, Sakamoto N, Ishimatsu Y, Fujii T, Koji T, Kohno S. Localization of HSP47 mRNA in murine bleomycin-induced pulmonary fibrosis[J].Virchows Arch, 2010, 456(3): 309–315.  
12American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias[J].Am J Respir Crit Care Med, 2002, 165(2): 277–304.  
13Hemmati AA, Rezaie A, Darabpour P. Preventive effects of pomegranate seed extract on bleomycin-induced pulmonary fibrosis in rat[J].Jundishapur J Nat Pharm Prod, 2013, 8(2): 76–80.  
14Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy[J].Ann Intern Med, 2001, 134(2): 136–151.  
15Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification[J].Am J Respir Crit Care Med, 1998, 157(4): 1301–1315.  
16Kuhn C 3rd, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis[J].Am Rev Respir Dis, 1989, 140(6): 1693–1703.  
17Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis[J].Am J Pathol, 1991, 138(5): 1257–1265.  
18Hemmati AA, Hicks R. Increased myofibroblast contractile sensitivity in paraquat pretreated rat lung tissue[J].Life Sci, 1999, 65(22): 2325–2332.  
19Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008; 40(3): 362–382.
20Martin GE, Ask K, Gilpin SE, Kolb M, Gauldie J. The transforming growth factor-beta (TGF-β) family and pulmonary fibrosis[J].Drug Discov Today Dis Mech, 2006, 3(1): 99–103.  
21Safaeian L, Dehkordi AJ, Afsharmoghaddam N, Sarahroodi S. The effects of Silymarin in bleomycin-induced pulmonary fibrosis in mice[J].Qom Univ Med Sci J, 2009, 3(2): 381–385.  
22Dinis-Oliveira RJ, Duarte JA, Sánchez-Navarro A, Remi?o F, Bastos ML, Carvalho F. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment[J].Crit Rev Toxicol, 2008, 38(1): 13–71.  
23Hemmati A, Nazari Z, Motlagh M, Goldasteh S. The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat[J].Pharmacol Res, 2002, 46(3): 229–234.  
24Mojiri-Forushani H, Hemmati AA, Khodadadi A, Assarehzadegan M, Rashno M. Protective effect of valsartan on beleomycin-induced fibrosis[J].Jundishapur J Nat Pharm Prod, 2017, 12(1): e33973.  
25Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J].N Engl J Med, 2014, 370(22): 2071–2082.  
26Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials[J].PLoS One, 2012, 7(10): e47024.  
27Javad-Mousavi SA, Hemmati AA, Mehrzadi S, Hosseinzadeh A, Houshmand G, Rashidi Nooshabadi MR, Mehrabani M, Goudarzi M. Protective effect of Berberis vulgaris fruit extract against paraquat-induced pulmonary fibrosis in rats[J].Biomed Pharmacother, 2016, 81: 329–336.  
28Chilakapati SR, Serasanambati M, Manikonda PK, Chilakapati DR, Watson RR. Passion fruit peel extract attenuates bleomycin-induced pulmonary fibrosis in mice[J].Can J Physiol Pharmacol, 2014, 92(8): 631–639.  
29Li L, Li D, Xu L, Zhao P, Deng Z, Mo X, Li P, Qi L, Li J, Gao J. Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats[J].Phytomedicine, 2015, 22(1): 111–119.  
30Ghorashi M, Rezaee MA, Rezaie MJ, Mohammadi M, Jalili A, Rahmani MR. The attenuating effect of aqueous extract of licorice on bleomycin-induced pulmonary fibrosis in mice[J].Food Agric Immunol, 2017, 28(1): 67–77.  
31Hemmati A, Arzi A, Adinehv A, Mostofi N, Mozaffari A, Jalali A. Yarrow (Achillea millefolium L.) extract impairs the fibrogenic effect of bleomycin in rat lung[J].J Med Plant Res, 2011, 5(10): 1843–1849.  
32Hemmati AA, Aghel N, Nazari Z, Mohammadian B, Hasanvand N. Protective effect of grape seed extract against the fibrogenic effect of bleomycin in rat lung[J].Iran J Pharm Sci, 2006, 2(3): 143–150.  
33Hemmati AA, Nazari Z, Samei M. A comparative study of grape seed extract and vitamin E effects on silica-induced pulmonary fibrosis in rats[J].Pulm Pharmacol Ther, 2008, 21(4): 668–674.  
34Asghari MH, Hobbenaghi R, Nazarizadeh A, Mikaili P. Hydro-alcoholic extract of Raphanus sativus L. var niger attenuates bleomycin-induced pulmonary fibrosis via decreasing transforming growth factor-β1 level[J].Res Pharm Sci, 2015, 10(5): 429–435.  
35Kar S, Konsam S, Hore G, Mitra S, Biswas S, Sinha A, Jana NR, Banerjee ER. Therapeutic use of fisetin, curcumin, and mesoporous carbaon nanoparticle loaded fisetin in bleomycin-induced idiopathic pulmonary fibrosis[J].Biomed Res Ther, 2015, 2(4): 250–262.  
36Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. Effect of glycosides-based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-κB, Muc5ac, TNF-α and IL-1β[J].Chem Biol Interact, 2015, 237: 151–165.  
37Zhan H, Huang F, Ma W, Zhao Z, Zhang H, Zhang C. Protective effect of ginsenoside Rg1 on bleomycin-induced pulmonary fibrosis in rats: involvement of caveolin-1 and TGF-β1 signal pathway[J].Biol Pharm Bull, 2016, 39(8): 1284–1292.  
38Malayeri AR, Hemmati AA, Arzi A, Rezaie A, Ghafurian-Boroojerdnia M, Khalili HR. A comparison of the effects of quercetin hydrate with those of vitamin E on the levels of IL-13, PDGF, TNF-α, and INF-γ in bleomycin-induced pulmonary fibrosis in rats. Jundishapur J Nat Pharm Prod. 2016; 11(2): e27705
39Verma R, Kushwah L, Gohel D, Patel M, Marvania T, Balakrishnan S. Evaluating the ameliorative potential of quercetin against the bleomycin-induced pulmonary fibrosis in Wistar rats. Pulm Med. 2013; 2013: 921724
40Chitra P, Saiprasad G, Manikandan R, Sudhandiran G. Berberine attenuates bleomycin-induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study[J].Toxicol Lett, 2013, 219(2): 178–193.  
41Nikbakht J, Hemmati AA, Arzi A, Mansouri MT, Rezaie A, Ghafourian M. Protective effect of gallic acid against bleomycin-induced pulmonary fibrosis in rats[J].Pharmacol Rep, 2015, 67(6): 1061–1067.  
42You H, Wei L, Sun WL, Wang L, Yang ZL, Liu Y, Zheng K, Wang Y, Zhang WJ. The green tea extract epigallocatechin-3-gallate inhibits irradiation-induced pulmonary fibrosis in adult rats[J].Int J Mol Med, 2014, 34(1): 92–102.  
43Larki-Harchegani A, Hemmati AA, Arzi A, Ghafurian-Boroojerdnia M, Shabib S, Zadkarami MR, Esmaeilzadeh S. Evaluation of the effects of caffeic acid phenethyl ester on prostaglandin E2 and two key cytokines involved in bleomycin-induced pulmonary fibrosis[J].Iran J Basic Med Sci, 2013, 16(7): 850–857.  
44Larki A, Hemmati AA, Arzi A, Borujerdnia MG, Esmaeilzadeh S, Zad Karami MR. Regulatory effect of caffeic acid phenethyl ester on type I collagen and interferon-gamma in bleomycin-induced pulmonary fibrosis in rat[J].Res Pharm Sci, 2013, 8(4): 243–252.  
45Zaeemzadeh N, Hemmati A, Arzi A, Jalali M, Rashidi I. Protective effect of caffeic acid phenethyl ester (CAPE) on amiodarone-induced pulmonary fibrosisin rat[J].Iran J Pharm Res, 2011, 10(2): 321–328.  
46Hemmati AA, Zaeemzadeh N, Arzi A, Jalali MT, Rashidi I. Impact of cafeic acid phenethyl ester (CAPE) on amiodarone-induced pulmonary fibrosis in rat[J].Toxicol Lett, 2009, 189: S168–S169.  
47Akgedik R, Akgedik S, Karamanli H, Uysal S, Bozkurt B, Ozol D, Armutcu F, Y?ld?r?m Z. Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats[J].Inflammation, 2012, 35(5): 1732–1741.  
48Hemmati AA, Kazemi M, Pashmforoosh M, Rajabi-Vardanjani H, Shabib S, Nili-Ahmadabadi A, Larki A. Sildenafil, a selective inhibitor of type 5 phosphodiesterase, attenuates bleomycin-induced lung fibrosis in rat. Biological Forum; 2015; 7(2): 1067–1071.
49Khodayar MJ, Kiani M, Hemmati AA, Rezaie A, Zerafatfard MR, Rashidi Nooshabadi MR, Goudarzi M. The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats[J].Adv Pharm Bull, 2014, 4(4): 345–349.  
50Mikaili P, Hemmati AA, Khodayar MJ, Ghafurian M, Rashidi I. The protective effect of penicillamine against bleomycine-induced pulmonary fibrosis in rats. Adv Environ Biol. 2012; 204–210.
51Mikaili P, Hemmati AA, Khodayar MJ, Ghafurian M, Rashidi I. Evaluation of the effects of nicotinamide on the bleomycin-induced pulmonary fibrosis in rat[J].Int J Anim Vet Adv, 2011, 3(5): 330–336.  
52Ermis H, Parlakpinar H, Gulbas G, Vardi N, Polat A, Cetin A, Kilic T, Aytemur ZA. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats[J].Naunyn-Schmiedeberg’s Arch Pharmacol, 2013, 386(12): 1103–1110.  
53Kalayarasan S, Sriram N, Soumyakrishnan S, Sudhandiran G. Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2[J].Toxicol Appl Pharmacol, 2013, 271(2): 184–195.  
54Hemmati AA, Mikaili P, Khodayar MJ, Ghafurian M, Rashidi I. The protective effect of cetirizine against bleomycin-induced pulmonary fibrosis in rats[J].Pak J Med Sci, 2008, 24(6): 813–820.  
55Hemmati AA, Nazari Z, Rashidi I, Kazemi Z. Protective effect of ketotifen on bleomycin-induced pulmonary fibrosis in rat[J].J Pharm Chem, 2008, 2(1): 65–68.  
56Guo F, Sun YB, Su L, Li S, Liu ZF, Li J, Hu XT, Li J. Losartan attenuates paraquat-induced pulmonary fibrosis in rats[J].Hum Exp Toxicol, 2015, 34(5): 497–505.  
57Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor[J].Am J Physiol Lung Cell Mol Physiol, 2000, 279(1): L143–L151.  
58Ghazi-Khansari M, Mohammadi-Karakani A, Sotoudeh M, Mokhtary P, Pour-Esmaeil E, Maghsoud S. Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats[J].J Appl Toxicol, 2007, 27(4): 342–349.  
59Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin-induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist[J].Thorax, 2004, 59(1): 31–38.  
60Marut W, Kavian N, Servettaz A, Hua-Huy T, Nicco C, Chéreau C, Weill B, Dinh-Xuan AT, Batteux F. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade[J].Arthritis Rheum, 2013, 65(5): 1367–1377.  
61Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice[J].Int Immunopharmacol, 2013, 17(2): 210–215.  
62Liu B, Cao B, Zhang D, Xiao N, Chen H, Li GQ, Peng SC, Wei LQ. Salvianolic acid B protects against paraquat-induced pulmonary injury by mediating Nrf2/Nox4 redox balance and TGF-β1/Smad3 signaling[J].Toxicol Appl Pharmacol, 2016, 309: 111–120.  
63Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M. Pioglitazone, a peroxisome proliferator-activated receptor γ ligand, suppresses bleomycin-induced acute lung injury and fibrosis[J].Respiration, 2009, 77(3): 311–319.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号